Durect corporation announces positive topline data from phase 1b study of dur-928 in nash

Durect corporation announces positive topline data from phase 1b study of dur-928 in nash.durect corp - improvements in both serum liver enzymes and liver imaging from phase 1b study of dur-928 in nash.durect corp - improvement in serum lipid profile from phase 1b study of dur-928 in nash.durect corp - dur-928 was well tolerated with no significant adverse events.
DRRX Ratings Summary
DRRX Quant Ranking